Lu S, Wu L, Wang Q, Wang Z, et al. Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study. J Thorac Oncol 2025;20:366-382.
PMID: 39521433